TCH-165

TCH-165 is a small molecule modulator of proteasome assembly , which increases 20S levels and facilitates 20S -mediated protein degradation In Vitro TCH-165 (0.01-10 μM; 72 hours; RPMI8226 and U87MG cells) treatment inhibits cell growth of RPMI8226 and U87MG cells with IC 50 of 1.6 μM and 2.4 μM, respectively. ? TCH-165 (0-10 μM; 24 hours; HEK293T cells) treatment enhances ODC degradation is blocked by BTZ indicated that this event is proteasome-mediated. TCH-165 enhances proteolytic degradation in a concentration-dependent manner. ? TCH-165 enhances the chymotrypsin-like (CT-L), trypsin-like (Tryp-L) and caspase-like (Casp-L) activities with EC 50 s of 4.2 μM, 3.2 μM and 4.7 μM, respectively. ? TCH-165 enhances 20S-mediated degradation of IDPs, α-syn, and tau in vitro, and does not induce the degradation of structured proteins such as GAPDH. ? TCH-165-treated cells display a decrease in the assembled 26S and an increase in the 20S proteasome. TCH-165 regulates the dynamic equilibrium between the 20S and 26S proteasome complexes, favoring 20S-mediated protein degradation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: RPMI8226 and U87MG cells Concentration: 0.01-10 μM Incubation Time: 72 hours Result: Inhibited cell growth of RPMI8226 and U87MG cells with IC 50 of 1.6 μM and 2.4 μM, respectively. Western Blot AnalysisCell Line: HEK293T cells Concentration: 0 μM, 3 μM, 10 μM Incubation Time: 24 hours Result: Enhanced proteolytic degradation in a concentration-dependent manner. Form:Solid IC50& Target:Proteasome assembly

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet